JP2020536107A5 - - Google Patents

Download PDF

Info

Publication number
JP2020536107A5
JP2020536107A5 JP2020519400A JP2020519400A JP2020536107A5 JP 2020536107 A5 JP2020536107 A5 JP 2020536107A5 JP 2020519400 A JP2020519400 A JP 2020519400A JP 2020519400 A JP2020519400 A JP 2020519400A JP 2020536107 A5 JP2020536107 A5 JP 2020536107A5
Authority
JP
Japan
Prior art keywords
vaccine composition
composition according
dengue
administered
vaccination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020519400A
Other languages
English (en)
Japanese (ja)
Other versions
JP7313345B2 (ja
JP2020536107A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/001219 external-priority patent/WO2019069130A1/en
Publication of JP2020536107A publication Critical patent/JP2020536107A/ja
Publication of JP2020536107A5 publication Critical patent/JP2020536107A5/ja
Application granted granted Critical
Publication of JP7313345B2 publication Critical patent/JP7313345B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020519400A 2017-10-05 2018-10-05 デング熱に対するブースターワクチン接種のための組成物 Active JP7313345B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762568525P 2017-10-05 2017-10-05
US62/568,525 2017-10-05
PCT/IB2018/001219 WO2019069130A1 (en) 2017-10-05 2018-10-05 COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE

Publications (3)

Publication Number Publication Date
JP2020536107A JP2020536107A (ja) 2020-12-10
JP2020536107A5 true JP2020536107A5 (cg-RX-API-DMAC7.html) 2021-11-11
JP7313345B2 JP7313345B2 (ja) 2023-07-24

Family

ID=64184125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020519400A Active JP7313345B2 (ja) 2017-10-05 2018-10-05 デング熱に対するブースターワクチン接種のための組成物

Country Status (6)

Country Link
US (2) US11690903B2 (cg-RX-API-DMAC7.html)
EP (1) EP3691681A1 (cg-RX-API-DMAC7.html)
JP (1) JP7313345B2 (cg-RX-API-DMAC7.html)
AU (1) AU2018346724B2 (cg-RX-API-DMAC7.html)
SG (1) SG11202002933TA (cg-RX-API-DMAC7.html)
WO (1) WO2019069130A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7313345B2 (ja) * 2017-10-05 2023-07-24 サノフィ・パスツール デング熱に対するブースターワクチン接種のための組成物
WO2022123470A1 (en) * 2020-12-10 2022-06-16 Reagene Biosciences Pvt. Ltd. Saliva based diagnostic assays for detection of sarscov2 receptor binding domain (rbd) neutralizing antibodies

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040933A1 (en) 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
ES2345614T3 (es) 1997-02-28 2010-09-28 Sanofi Pasteur Biologics Co. Vacunas quimericas de flavivirus.
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
JP2002540169A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱1型ウイルスワクチン
US6537557B1 (en) 1999-03-26 2003-03-25 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-4 virus vaccine
WO2000057909A2 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-2 virus vaccine
JP2002540166A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱3型ウイルスワクチン
AU1813901A (en) 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
DK2278012T3 (en) 2000-02-16 2015-12-07 Us Government Immunogenic dengue 2 virus chimeras
DE60040652D1 (de) 2000-05-30 2008-12-11 Univ Mahidol Attenuierte Stammen von Denguevirus und ihre Verwendungen in Impfstoffzusammensetzungen
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
CA2755964C (en) 2001-05-22 2017-06-27 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
EP1401859B1 (en) 2001-06-01 2013-08-07 Sanofi Pasteur Biologics Co. Chimeric flavivirus vectors
JP2005519639A (ja) 2002-01-15 2005-07-07 アカンビス インコーポレーティッド フラビウイルスワクチン
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
AU2003239932A1 (en) 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
DE602006015807D1 (de) 2005-06-17 2010-09-09 Ct S For Disease Control & Pre Abgeschwächter dengue-serotyp-2-stamm
WO2006134433A1 (en) 2005-06-17 2006-12-21 Sanofi Pasteur Dengue serotype 1 attenuated strain
WO2007021672A2 (en) 2005-08-10 2007-02-22 Acambis Inc. Vaccination against dengue virus infection
KR101357685B1 (ko) 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 재조합 바이러스용 안정화 제형
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
US7968102B2 (en) 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
US8591916B2 (en) 2007-01-31 2013-11-26 Sanofi Pasteur Biologics, Llc Flavivirus vaccine vector against influenza virus
US8715689B2 (en) 2008-04-30 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric west nile/dengue viruses
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
US20120201846A1 (en) 2009-07-29 2012-08-09 Bernd Helmut Adam Rehm Polymer particles and uses thereof
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
GB201007531D0 (en) 2010-05-05 2010-06-23 Imp Innovations Ltd Composition
CN102906266A (zh) 2010-05-21 2013-01-30 高等教育联邦系统-匹兹堡大学 登革病毒通用序列及其使用方法
WO2012051491A1 (en) 2010-10-14 2012-04-19 The United States Of America, As Represented By The Secretary National Institutes Of Health Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
KR20150036592A (ko) 2012-07-24 2015-04-07 사노피 파스퇴르 백신 조성물
US20150265695A1 (en) 2012-07-24 2015-09-24 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
US10518409B2 (en) * 2014-09-02 2019-12-31 Mark Oleynik Robotic manipulation methods and systems for executing a domain-specific application in an instrumented environment with electronic minimanipulation libraries
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
WO2017005654A1 (en) 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination.
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
JP7313345B2 (ja) * 2017-10-05 2023-07-24 サノフィ・パスツール デング熱に対するブースターワクチン接種のための組成物

Similar Documents

Publication Publication Date Title
Chen et al. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement
Cai et al. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses
Minor Live attenuated vaccines: Historical successes and current challenges
Foo et al. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide
Ikegami et al. Rift valley fever vaccines
Simmons et al. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy
Zhou et al. Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys
JP2019151636A5 (cg-RX-API-DMAC7.html)
Xiang et al. Protection of non-human primates against rabies with an adenovirus recombinant vaccine
Baehner et al. Vaccines against norovirus: state of the art trials in children and adults
Bröker et al. After a tick bite in a tick-borne encephalitis virus endemic area: current positions about post-exposure treatment
Terhuja et al. Comparative efficacy of virus like particle (VLP) vaccine of foot-and-mouth-disease virus (FMDV) type O adjuvanted with poly I: C or CpG in guinea pigs
Martinelle et al. Assessment of cross-protection induced by a bluetongue virus (BTV) serotype 8 vaccine towards other BTV serotypes in experimental conditions
JP2017526689A5 (cg-RX-API-DMAC7.html)
CN113329767B (zh) 肠道病毒对vero细胞的适应及其疫苗制剂
Moreno et al. Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge
Abente et al. Alphavirus-vectored hemagglutinin subunit vaccine provides partial protection against heterologous challenge in pigs
Calvo-Pinilla et al. Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48 h after challenge
Calvo-Pinilla et al. The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host
Phillpotts et al. Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus
JP2024520730A5 (cg-RX-API-DMAC7.html)
Zhang et al. Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71
Zhou et al. Recombinant adenovirus expressing type Asia1 foot-and-mouth disease virus capsid proteins induces protective immunity against homologous virus challenge in mice
Steil et al. A mucosal adjuvant for the inactivated poliovirus vaccine
Van Rijn et al. Bluetongue Disabled Infectious Single Animal (DISA) vaccine: Studies on the optimal route and dose in sheep